Monitoring the Future Survey/Lifetime Use Scale

Abstract

The Monitoring the Future Survey – Lifetime Use Scale (MTF-LUS) is an epidemiological and psychometric measurement instrument designed to assess cumulative lifetime experimentation and consumption across a spectrum of licit and illicit psychoactive substances among adolescents and young adults. Originating from the landmark Monitoring the Future (MTF) research program inaugurated in 1975 by principal investigators Lloyd D. Johnston, Patrick M. O’Malley, and Jerald G. Bachman at the University of Michigan Institute for Social Research (ISR), and sponsored by the National Institute on Drug Abuse (NIDA), the scale serves as a standardized global benchmark in substance use epidemiology. The core Lifetime Use Scale consists of multi-item substance-specific modules evaluating initiation and cumulative frequency of use across classes including combustible cigarettes, smokeless tobacco, alcohol, subjective alcohol intoxication (drunkenness), cannabis (marijuana/hashish), volatile inhalants, prescription stimulants used nonmedically (amphetamines), and cocaine in both crack and powder forms. Items are scored on variable response formats ranging from dichotomous responses to 4-point ordinal and standardized 7-point semi-logarithmic frequency scales ranging from “0 occasions” to “40 or more occasions.” Extensive psychometric evaluations over five decades have confirmed high construct validity, robust criterion validity when evaluated against collateral biological and longitudinal markers, excellent test-retest reliability coefficients ($r_{tt} > .80$), and consistent factor structures across demographic groups. The instrument also forms a primary component of the Center for Substance Abuse Prevention (CSAP) Core Measures Initiative, functioning as an indispensable tool for longitudinal surveillance, etiology research, and public health intervention modeling.

Keywords

Monitoring the Future, Lifetime Use Scale, substance use epidemiology, adolescent drug use, psychometrics, cumulative substance exposure, test-retest reliability, structural equation modeling, CSAP core measures, longitudinal surveillance.

Authors

The Monitoring the Future Survey and its constituent Lifetime Use Scale were developed and maintained by senior research scientists at the Survey Research Center within the Institute for Social Research at the University of Michigan, Ann Arbor:

• Lloyd D. Johnston, Ph.D. – Research Professor Emeritus, Survey Research Center, Institute for Social Research, University of Michigan. Contact: [email protected].
• Patrick M. O’Malley, Ph.D. – Research Professor Emeritus, Survey Research Center, Institute for Social Research, University of Michigan.
• Jerald G. Bachman, Ph.D. – Research Professor Emeritus, Survey Research Center, Institute for Social Research, University of Michigan.
• Subsequent Principal Investigators & Co-Investigators: Richard A. Miech, Ph.D.; John E. Schulenberg, Ph.D.; Megan E. Patrick, Ph.D.; and Yvonne M. Terry-McElrath, MSA, Institute for Social Research, 426 Thompson Street, Ann Arbor, MI 48104-2321.

Purpose

The overarching purpose of the Monitoring the Future Survey – Lifetime Use Scale (MTF-LUS) is to measure lifetime cumulative prevalence, initiation milestones, and the developmental escalation of substance use among youth, emerging adults, and adult populations. By assessing whether an individual has ever consumed a specific substance in their lifetime, as well as quantifying the total volume of lifetime occasions, the scale differentiates between transient, experimental initiation and deeply entrenched, repeated polysubstance involvement.

Within public health and epidemiological surveillance, the scale provides critical macro-level data required to detect shifts in drug epidemics, emerging drug trends (e.g., historical transitions from powdered cocaine to crack cocaine, or historical surges in nonmedical prescription stimulant misuse), and the demographic correlates of adolescent risk-taking. In scientific research, the MTF-LUS functions as a baseline anchor for longitudinal prospective cohort studies, permitting scholars to examine causal trajectories, developmental gateways, and long-term neurocognitive, socioeconomic, and psychiatric outcomes tied to early age of onset and high cumulative exposure.

In clinical, community, and educational evaluation contexts, the MTF-LUS serves as an integral component of the Substance Abuse and Mental Health Services Administration (SAMHSA) and Center for Substance Abuse Prevention (CSAP) Core Measures Initiative. Community-based prevention programs deploy the instrument to establish baseline prevalence rates against which primary and secondary prevention interventions can be empirically benchmarked. The clinical utility of measuring lifetime exposure resides in its capacity to identify individuals who have progressed past initial experimentation into threshold frequencies (such as 10–19, 20–39, or 40+ lifetime occasions) that are statistically correlated with DSM-5 Substance Use Disorder criteria, neurobehavioral sensitization, and physiological dependence.

Psychological Construct

The primary psychological construct captured by the MTF-LUS is lifetime cumulative substance involvement, which is operationalized through behavioral engagement across distinct pharmacological classes. Rather than viewing drug involvement purely as a binary state (use vs. non-use), the MTF-LUS framework operationalizes it as a dimensional continuum of cumulative behavioral acquisition, spanning non-initiation, initial experimentation, exploratory social use, and repeated behavioral maintenance.

The scale systematically measures several discrete operational facets:

• Nicotine and Tobacco Exposure: Measured across combustible cigarettes and smokeless tobacco products. The construct reflects early behavioral deviance, social modeling, and susceptibility to habit-forming neurochemical reinforcement. Responses assess transitions from single-trial experimentation (“Once or twice”) to historical lifestyle consolidation (“Regularly in the past”).
• Alcohol Exposure and Intoxication: The instrument distinguishes between alcohol consumption (having had more than a few sips) and the subjective experience of acute pharmacological intoxication (“drunk or very high”). This distinction is critical in developmental psychology, as the neurobiological and psychosocial sequelae of alcohol misuse stem more directly from neurotoxic peak blood alcohol concentrations (binge episodes and drunkenness) than from incidental sips.
• Cannabis Involvement: Captures cumulative lifetime experimentation with THC-bearing substances (marijuana, hashish, hash oil). This dimension serves as a foundational marker in models of substance use progression, social norm transgression, and externalizing behavioral phenotypes.
• Volatile Inhalant Misuse: Involves deliberate chemical inhalation (glue, aerosol propellants, solvents, industrial gases) to induce altered psychological states. Inhalant use represents a specialized construct indicative of early-onset substance experimentation, low-cost accessibility, heightened neurotoxicity risk, and elevated psychopathology among younger adolescents.
• Illicit and Nonmedical Prescription Stimulant Misuse: Evaluates unsupervised consumption of amphetamines, central nervous system stimulants, and related prescription compounds taken without medical instruction. This dimension measures functional pharmacological self-enhancement, academic performance pressure, or recreational euphoria-seeking.
• Cocaine and High-Potency Psychostimulant Consumption: Disaggregates freebase/crack cocaine from powdered cocaine hydrochloride. This construct captures engagement with high-reinforcing, illicit, stigmatized substances, typically indexing severe deviance, high addiction liability, and progression to extreme ends of the risk spectrum.

Theoretical Framework

The theoretical architecture underpinning the MTF-LUS integrates several major psychological and sociological frameworks of adolescent risk behavior, primarily Problem Behavior Theory, the Gateway Hypothesis / Developmental Cascades, and Social Development and Ecological Systems Models.

According to Problem Behavior Theory (Jessor & Jessor, 1977), substance use is not an isolated, irrational aberration; rather, it is part of a larger, functionally organized constellation of norm-violating behaviors driven by the interaction of three systems: the Personality System (e.g., values, expectations, tolerance of deviance), the Perceived Environment System (e.g., peer models, parental controls), and the Behavior System (e.g., delinquency, academic underachievement, and substance use). Within this framework, cumulative lifetime substance use items quantify the respondent’s level of behavioral transition away from conventional societal expectations toward nonconventional deviance.

Complementing this is Denise Kandel’s Gateway Hypothesis and modern Developmental Cascade Models (Kandel, 2002), which postulate that drug-taking behavior unfolds in a predictable, stage-sequential sequence. Adolescents typically initiate with socially accessible, licit substances (beer, wine, cigarettes), transition to hard liquor and cannabis, and subsequently may progress to illicit stimulants (amphetamines, cocaine) and other controlled substances. The MTF-LUS was specifically constructed with graded substance categories to empirically verify these developmental pathways, enabling researchers to track transitions across developmental thresholds.

Additionally, the scale is interpreted through Catalano and Hawkins’s Social Development Model and Bronfenbrenner’s Ecological Systems Theory. These models emphasize how micro-systemic interactions (family bonding, school commitment, peer association) either insulate adolescents against or shepherd them into drug-using peer networks. The quantitative gradations of the MTF-LUS capture the degree to which an adolescent has become socialized into substance-using subcultures, wherein frequent consumption (≥40 occasions) signifies comprehensive behavioral acculturation into substance-centric social environments.

Validity

The psychometric validity of the Monitoring the Future Lifetime Use Scale has been corroborated by hundreds of empirical investigations over five decades of nationwide administration.

Construct and Structural Validity: Factor-analytic and item response theory (IRT) investigations confirm that the MTF-LUS items map onto a coherent, hierarchical substance-use continuum. Cumulative lifetime use items demonstrate severe monotonically increasing threshold parameters across drug classes, adhering precisely to hypothesized developmental difficulty hierarchies (where inhalants, crack, and powder cocaine occupy the high-severity tail of the latent trait θ).

Predictive and Longitudinal Criterion Validity: Long-term panel studies conducted by Johnston, O’Malley, Bachman, and Schulenberg have tracked MTF cohorts from age 18 across biennial follow-ups into midlife (ages 35, 40, 50, and beyond). High baseline scores on lifetime alcohol intoxication, cannabis use, and nonmedical stimulant use prospectively predict adult substance use disorders, marital instability, psychiatric morbidity, and socioeconomic difficulties. Furthermore, baseline lifetime non-users who report early initiation in 8th or 10th grade exhibit markedly heightened trajectories of heavy episodic drinking and polysubstance misuse in early adulthood compared to late-onset peers.

Concurrent and Convergent Validity: MTF-LUS scores correlate strongly with collateral markers of behavioral disinhibition, school truancy, academic failure, sensation seeking, and self-reported delinquency ($r = .45$ to $.65$). In addition, studies comparing MTF regional estimates with independent biological markers (e.g., urinalysis, hair testing) and external epidemiological surveillance systems (such as the National Survey on Drug Use and Health [NSDUH] and the Youth Risk Behavior Surveillance System [YRBSS]) show exceptionally high cross-instrument congruence, typically yielding cross-survey prevalence correlations exceeding $r = .90$ for core substances.

Discriminant Validity: The scale reliably differentiates between experimental curiosity and compulsive substance engagement. Individuals reporting “1–2 occasions” exhibit psychosocial profiles substantially more similar to complete abstainers than to individuals reporting “20–39” or “40 or more” occasions, who demonstrate marked psychological distress, sensation-seeking, and severe school disengagement.

Reliability

Because the MTF-LUS spans multiple distinct drug classes rather than homogeneous, interchangeable items of a singular affective state, classical internal consistency measures (such as Cronbach’s $\alpha$) must be interpreted with caution. Nevertheless, when composite illicit drug use indices are constructed across illicit substances (e.g., cannabis, inhalants, amphetamines, crack, and powder cocaine), internal consistency reliabilities consistently range between $\alpha = .78$ and $.86$.

The principal reliability benchmark for lifetime retrospective reporting is test-retest reliability and longitudinal response consistency over time. In a definitive psychometric study by O’Malley, Bachman, and Johnston (1983), the stability of MTF lifetime drug use reports was evaluated across repeated annual measurements. Pearson test-retest correlation coefficients ($r_{tt}$) across a one-year follow-up interval for lifetime prevalence of marijuana, alcohol, and cigarette use were found to be exceptionally high, typically between $.82$ and $.92$.

Furthermore, researchers have rigorously investigated the phenomenon of retrospective recantation (i.e., an individual reporting lifetime substance use in an earlier wave, but subsequently reporting non-use in a later wave). Within the MTF longitudinal panels, the overall recantation rate across high school and post-high school waves is remarkably low (averaging below 2% to 4% for highly memorable substances such as marijuana or alcohol), demonstrating robust memory retrieval fidelity and high response stability in confidential, well-standardized testing conditions.

Factor Analysis

Numerous exploratory factor analyses (EFA) and confirmatory factor analyses (CFA) have examined the structural architecture of the MTF substance use indicators. When analyzing the lifetime use items, psychometricians generally observe a hierarchical two-tier or bi-factor structure:

• General Substance Vulnerability Dimension ($g$-Substance Factor): A pervasive overarching factor that captures a general latent liability toward externalizing deviance and chemical experimentation. All lifetime items load positively onto this general dimension, with standardized factor loadings ranging from $.52$ (cigarette use) to $.88$ (marijuana and amphetamine use).
• Specific Substance-Class Dimensions: Residual variance analysis routinely yields three distinct, highly correlated subfactors:
  • Licit / Social Gateway Factor: Comprising combustible cigarettes, smokeless tobacco, and general alcohol consumption (loadings $.60 – .82$).
  • Cannabinoid / Soft Drug Factor: Dominated by marijuana and hashish use and drunkenness/acute intoxication (loadings $.74 – .89$).
  • Hard Illicit / Deviant Substance Factor: Highly specific to inhalants, nonmedical amphetamines, powdered cocaine, and crack cocaine (loadings $.68 – .91$).

In structural equation modeling (SEM) investigations evaluating measurement invariance, confirmatory models demonstrate excellent fit indices across diverse demographic strata (e.g., Root Mean Square Error of Approximation [RMSEA] $le .045$, Comparative Fit Index [CFI] $ge .96$, Tucker-Lewis Index [TLI] $ge .95$, Standardized Root Mean Square Residual [SRMR] $le .038$). Crucially, multi-group confirmatory factor analysis (MGCFA) supports strict metric and scalar invariance across sex (male vs. female) and racial/ethnic groups (White, Black, Hispanic), validating that the items evaluate identical constructs with equivalent scaling metrics across heterogeneous youth populations.

Instrument / Measurement Tool

• Instrument Name: Monitoring the Future Survey – Lifetime Use Scale (MTF-LUS).
• Primary Reference Source: Johnston, L. D., O’Malley, P. M., & Bachman, J. G. (2001); Center for Substance Abuse Prevention (CSAP) Core Measures Initiative.
• Administration Format: Self-administered paper-and-pencil or computerized questionnaire (web-based and digital tablets in contemporary iterations), designed for confidential classroom or individual survey environments.
• Item Count: 10 standard core items covering 8 distinct drug classes: combustible cigarettes, smokeless tobacco, alcohol use, alcohol intoxication (drunkenness), cannabis, volatile inhalants, nonmedical amphetamines/stimulants, crack cocaine, and powder cocaine.
• Response Formats:
  • Items 1 & 2 (Tobacco): 4-point ordinal scale (1 = “Never”, 2 = “Once or twice”, 3 = “Occasionally”, 4 = “Regularly in the past”).
  • Item 3 (Alcohol initiation screen): Dichotomous (1 = “No”, 2 = “Yes”).
  • Items 4, 5, 6, 7, 8, 9, 10 (Substance frequency modules): Standardized 7-point semi-logarithmic ordinal scale: 1 = “0 occasions”, 2 = “1–2 occasions”, 3 = “3–5 occasions”, 4 = “6–9 occasions”, 5 = “10–19 occasions”, 6 = “20–39 occasions”, 7 = “40 or more”.
• Scoring and Transformation Procedures:
  • Prevalence Dichotomization: For epidemiological surveillance, each substance item is collapsed into a binary lifetime prevalence rate (0 = No lifetime use / 0 occasions; 1 = Lifetime use ≥ 1 occasion / Once or twice).
  • Polysubstance Indexing: Summation of positive endorsements across illicit drug categories (e.g., cannabis, inhalants, amphetamines, crack, and other cocaine) creates a Polysubstance Lifetime Exposure Index (score range: 0 to 5 or higher).
  • Cumulative Exposure Scaling: For psychometric regression and SEM analyses, items are treated as continuous, quasi-continuous, or ordinal indicators. Midpoint recoding (e.g., 1–2 = 1.5, 3–5 = 4, 6–9 = 7.5, 10–19 = 14.5, 20–39 = 29.5, 40+ = 45 or 50) is frequently deployed to estimate aggregate lifetime doses or volumetric occasion counts.

Permissions & Fee and Test Year

The Monitoring the Future Survey was established in 1975 by Lloyd D. Johnston, Jerald G. Bachman, and Patrick M. O’Malley. The Lifetime Use Scale modules have been administered continuously since that time, with regular updates to reflect modern pharmacological nomenclature (such as brand names for prescription stimulants). As a federally funded research instrument supported continuously by research grants from the National Institute on Drug Abuse (Grant No. R01 DA001411), the survey items are placed in the public domain for academic, scientific, and public health research purposes.

No licensing fees, user fees, or royalty payments are required to administer the scale in non-commercial academic research, institutional surveys, or community program evaluations. However, researchers are requested to cite the original source publications and acknowledge the Institute for Social Research at the University of Michigan in published work. Detailed documentation, survey questionnaires, codebooks, and raw data files are archived and publicly accessible through the Inter-university Consortium for Political and Social Research (ICPSR / NAHDAP).

References

• Bachman, J. G., Johnston, L. D., & O’Malley, P. M. (1998). Explaining recent increases in students’ marijuana use: Impacts of perceived risks and disapproval, 1976–1996. American Journal of Public Health, 88(6), 887–892. https://doi.org/10.2105/AJPH.88.6.887
• Center for Substance Abuse Prevention. (2001). Core Measures Initiative Phase I Recommendations (pp. 23–26). Substance Abuse and Mental Health Services Administration (SAMHSA).
• Jessor, R., & Jessor, S. L. (1977). Problem behavior and psychosocial development: A longitudinal study of youth. Academic Press.
• Johnston, L. D., O’Malley, P. M., & Bachman, J. G. (2001). Monitoring the Future national survey results on drug use, 1975–2000: Volume I, Secondary school students (NIH Publication No. 01-4924). National Institute on Drug Abuse.
• Johnston, L. D., Miech, R. A., O’Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick, M. E. (2021). Monitoring the Future national survey results on drug use, 1975–2020: Overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan. https://doi.org/10.3998/2027.42/167812
• Kandel, D. B. (Ed.). (2002). Stages and pathways of drug involvement: Examining the gateway hypothesis. Cambridge University Press. https://doi.org/10.1017/CBO9780511499579
• Miech, R. A., Johnston, L. D., O’Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick, M. E. (2022). Trends in use and perceptions of nicotine vaping among US youth from 2017 to 2020. JAMA Pediatrics, 175(2), 185–190. https://doi.org/10.1001/jamapediatrics.2020.5667
• O’Malley, P. M., Bachman, J. G., & Johnston, L. D. (1983). Reliability and consistency in self-reports of drug use. International Journal of the Addictions, 18(6), 805–824. https://doi.org/10.3109/10826088309027371

13. Items of the Scale (Questionnaire)